[HTML][HTML] Phase 1 Lymfactin® study: 24-month efficacy and safety results of combined adenoviral VEGF-C and lymph node transfer treatment for upper extremity …
IM Leppäpuska, P Hartiala, S Suominen… - Journal of Plastic …, 2022 - Elsevier
ABSTRACT BACKGROUND Lymphedema is a common problem after breast cancer
treatment. Lymfactin® is a prolymphangiogenic growth factor vector inducing the expression
of human vascular endothelial growth factor C (VEGF-C). It promotes growth and repair of
lymphatic vessels. METHODS Lymfactin® was combined with microvascular lymph node
transfer surgery (VLNT) to study the safety and efficacy of the treatment in breast cancer-
related upper limb lymphedema (BCRL) patients. This is a continuation study with a 3 year …
treatment. Lymfactin® is a prolymphangiogenic growth factor vector inducing the expression
of human vascular endothelial growth factor C (VEGF-C). It promotes growth and repair of
lymphatic vessels. METHODS Lymfactin® was combined with microvascular lymph node
transfer surgery (VLNT) to study the safety and efficacy of the treatment in breast cancer-
related upper limb lymphedema (BCRL) patients. This is a continuation study with a 3 year …